Sphera Funds Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Sphera Funds Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-874,407	Closed	-$4.36M	–	140
2018 Q2	$4.36M	Buy	874,407 +40,774	+5%	+$178K	0.6%	49
2018 Q1	$3.25M	Hold	833,633	–	–	0.49%	58
2017 Q4	$2.23M	Hold	833,633	–	–	0.26%	89
2017 Q3	$2.66M	Buy	+833,633	New	+$2.78M	0.38%	69
2015 Q1	–	Sell	-75,000	Closed	-$1.77M	–	186
2014 Q4	$1.77M	Buy	+75,000	New	+$1.73M	0.3%	95
2014 Q2	–	Sell	-40,000	Closed	-$1.36M	–	148
2014 Q1	$1.36M	Buy	+40,000	New	+$1.37M	0.31%	68

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sphera Funds Management's CTIC Position: Q3 2018 in Review

Sphera Funds Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2018, closing a stake of 874,407 shares — an estimated $4.36M sold.

Sphera Funds Management first reported a position in CTIC in Q1 2014 and held it in 6 quarters. The position peaked at $4.36M in Q2 2018. 79 funds tracked by Wall St. Rank hold CTIC as of Q3 2018.

Sphera Funds Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2018 after selling out during the quarter.
Sphera Funds Management sold 874,407 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2018, an estimated $4.36M.
Sphera Funds Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 6 quarters.
Sphera Funds Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.36M in Q2 2018.
79 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2018.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.